Skin permeation of physostigmine from fatty acids-based formulations: Evaluating the choice of solvent

International Journal of Pharmaceutics

Volumn 290, Issue 1-2, 2005, Pages 25-36

  Wang, Mei Yin ^a,b   Yang, Yi Yan ^a   Heng, Paul Wan Sia ^b  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Enhancement mechanism; Fatty acids; Physostigmine; Skin permeation; Solvent effect

Indexed keywords

FATTY ACID; LIPID; MINERAL OIL; PHYSOSTIGMINE; PROPYLENE GLYCOL; SOLVENT;

ANIMAL TISSUE; ARTICLE; CHEMICAL INTERACTION; CONDUCTOMETRY; CONTROLLED STUDY; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; EVALUATION; FORCE; LIPID BILAYER; LIPOPHILICITY; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SKIN PERMEABILITY; STRATUM CORNEUM;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS; PHYSOSTIGMINE; SKIN ABSORPTION; SOLVENTS; SWINE;

EID: 12344317024     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.10.027     Document Type: Article

References (24)

1. B.J. Aungst Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants Pharm. Res. 6 1989 244 247
2. B.J. Aungst, J.A. Blake, and M.A. Hussain Contributions of drug solubilization, partitioning barrier and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines Pharm. Res. 7 1990 712 718
3. B.J. Aungst, N.J. Rogers, and E. Shefter Enhancement of naxolone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides Int. J. Pharm. 33 1986 225 234
4. Coelho Filho, J.M., Birks, J., 2001. Physostigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library Article 2.
5. B.M. Elyan, M.B. Sidhom, and F.M. Plakogiannis Evaluation of the effect of different fatty acids on the percutaneous absorption of metaproterenol sulphate J. Pharm. Sci. 85 1996 101 105
6. M.L. Francoeur, G.M. Golden, and R.O. Potts Oleic acid: its effects on stratum corneum in relation to (trans)dermal drug delivery Pharm. Res. 7 1990 621 627
7. G.M. Golden, J.E. McKie, and R.O. Potts Role of stratum corneum lipid fluidity in transdermal drug flux J. Pharm. Sci. 76 1987 25 28
8. P.G. Green, R.H. Guy, and J. Hadgraft In vitro and in vivo enhancement of skin permeation with oleic acid and lauric acid Int. J. Pharm. 48 1988 103 111
9. P.G. Green, and J. Hadgraft Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid Int. J. Pharm. 37 1987 251 255
10. P. Hartvig, L. Wiklund, and B. Lindstrom Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients Acta Anesthesiol. Scand. 30 1986 177 182
11. J. Jenner, A. Saleem, and D. Swanston Transdermal delivery of physostigmine. A pretreatment against organophosphate poisoning J. Pharm. Pharmacol. 47 1995 206 212
12. K. Kandimalla, N. Kanikkannan, S. Andega, and M. Singh Effect of fatty acids on the permeation of melatonin across rat and pig skin in-vitro and on the transepidermal water loss in rats in-vivo J. Pharm. Pharmacol. 51 1999 783 790
13. W.J. Krall, J.J. Sramek, and N.R. Cutler Cholinesterase inhibitors: strategy for Alzheimer disease Ann. Pharmacother. 33 1999 441 450
14. M.A. Pellett, M.S. Roberts, and J. Hadgraft Supersaturated solutions evaluated with an in vitro stratum corneum tape stripping technique Int. J. Pharm. 151 1997 91 98
15. S. Rubnov, D. Levy, and H. Schneider Liquid chromatographic analysis of physostigmine salicylate and its degradation products J. Pharm. Biomed. Anal. 18 1999 939 945
16. R.P. Solana, L.W. Harris, W.H. Carter, B.G. Talbot, U.A. Carchman, and C. Gennings Evaluation of a two-drug combination pretreatment against organophosphate exposure Toxicol. Appl. Pharmacol. 102 1990 421 429
17. P.W. Stott, A.C. Williams, and B.W. Barry Mechanistic study into the enhanced transdermal permeation of a model β-blocker, propranolol, by fatty acids: a melting point depression effect Int. J. Pharm. 219 2001 161 176
18. H. Tanojo, J.A. Bouwstra, H.E. Junginger, and H.E. Bodde In vitro human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies Pharm. Res. 14 1997 42 49
19. H. Tanojo, and H.E. Junginger Skin permeation enhancement by fatty acids J. Disper. Sci. Technol. 20 1999 127 138
20. K. Tuovinen, E.K. Korhonen, F.M. Raushel, and O. Hänninen Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication Toxicology 134 1999 169 178
21. H.K. Vaddi, P.C. Ho, Y.W. Chan, and S.W. Chan Terpenes in ethanol: haloperidol permeation and partition through human skin and stratum corneum changes J. Controlled Release 81 2002 121 133
22. K. Walter, M. Muller, M.F. Barkworth, A.V. Nieciecki, and F. Stanislaus Pharmacokinetics of physostigmine in man following a single application of a transdermal system Br. J. Clin. Pharmacol. 39 1995 59 63
23. M.Y. Wang, Y.Y. Yang, and P.W.S. Heng Role of solvent in interactions between fatty acid-based formulations and lipids in porcine stratum corneum J. Controlled Release 94 2004 207 216
24. A.C. Williams, and B.W. Barry Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement Pharm. Res. 8 1991 17 24